ORM2 Antibody

What is ORM2 and why is it important in research?

ORM2 (Orosomucoid 2) is a secreted protein belonging to the Lipocalin family with a length of 201 amino acid residues and a molecular mass of approximately 23.6 kDa. It functions primarily as a transport protein in the bloodstream and undergoes N-glycosylation as a post-translational modification. ORM2 is also known by several synonyms including AGP-B', AGP2, alpha-1-acid glycoprotein 2, and OMD 2 .

The protein is predominantly expressed by the liver and secreted into plasma, where its concentration can increase 10 to 200-fold within 24 hours in response to various stressful stimuli such as bacterial infections or physical trauma . This acute phase response characteristic makes ORM2 a valuable research target for understanding inflammatory conditions and immune modulation.

Recent studies have uncovered novel functions of ORM2 beyond its classical role as a plasma transport protein, including its expression in brain astrocytes and potential tumor-suppressive functions in hepatocellular carcinoma, expanding its significance in neuroinflammation and cancer research contexts .

What are the primary applications for ORM2 antibodies in research?

ORM2 antibodies serve multiple experimental purposes in research settings. The most common applications include:

• Western Blotting: For detecting and quantifying ORM2 protein expression in tissue or cell lysates

• Immunohistochemistry (IHC): For visualizing ORM2 protein distribution in tissue sections

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement of ORM2 in biological fluids or cell culture supernatants

Advanced applications include tracking changes in ORM2 expression during disease progression, monitoring responses to experimental treatments, and investigating protein-protein interactions. For neuroinflammation studies, researchers utilize ORM2 antibodies to examine astrocyte-microglial interactions and evaluate potential therapeutic interventions targeting neuroinflammatory processes .

How should researchers choose between polyclonal and monoclonal ORM2 antibodies?

The choice between polyclonal and monoclonal ORM2 antibodies depends on the specific research application and experimental objectives:

Polyclonal ORM2 antibodies recognize multiple epitopes on the ORM2 protein, making them advantageous for applications requiring:

• Higher sensitivity when protein abundance is low

• Detection of denatured proteins in Western blots

• Robust signals in immunohistochemistry applications

For example, mouse-reactive polyclonal antibodies are available that perform well in Western blotting and IHC applications, offering versatility across multiple detection methods .

Monoclonal ORM2 antibodies recognize a single epitope with high specificity, providing:

• Greater consistency between experimental batches

• Lower background noise in sensitive applications

• Superior performance in applications requiring precise epitope recognition

• Potentially better performance in quantitative assays

Research requiring reproducible results across multiple studies should consider recombinant monoclonal antibodies, such as rabbit-derived anti-human ORM2 monoclonal antibodies that offer consistent performance in Western blotting and immunohistochemistry applications .

What protocols are recommended for ORM2 antibody validation?

Thorough antibody validation is essential for generating reliable research data. For ORM2 antibodies, the following validation protocols are recommended:

• Positive and negative control tissues/cells: Use liver tissue (high ORM2 expression) as a positive control, and tissues known not to express ORM2 as negative controls.

• Knockout/knockdown verification: Validate antibody specificity using ORM2 knockdown approaches, as demonstrated in studies using lentiviral shRNA-mediated Orm2 knockdown .

• Western blot analysis: Confirm the antibody detects a band of appropriate molecular weight (approximately 23.6 kDa for the native protein, though glycosylation may alter the apparent weight).

• Cross-reactivity testing: Test for potential cross-reactivity with related proteins, particularly ORM1 and ORM3, especially important when studying mouse models as all three Orm genes exist in mice .

• Multiple detection methods: Validate findings using at least two independent detection methods (e.g., Western blot and IHC) to confirm expression patterns.

What are the optimal experimental conditions for ORM2 antibody-based immunohistochemistry?

When conducting immunohistochemistry with ORM2 antibodies, researchers should consider these methodological details:

• Fixation: Standard formalin fixation and paraffin embedding protocols work well for ORM2 detection in tissue samples.

• Antigen retrieval: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) is typically effective for unmasking ORM2 epitopes.

• Antibody dilution: Optimal antibody dilutions should be determined empirically, but typically range from 1:100 to 1:1000 depending on the specific antibody concentration and detection system .

• Detection systems: Both colorimetric (such as DAB) and fluorescence-based detection systems can be used effectively with ORM2 antibodies.

• Scoring system: Consider implementing a standardized scoring system similar to that used in published studies, where intensity of ORM2 immunostaining was scored as 0 (weak) or 1 (strong) to enable statistical correlations with clinical parameters .

• Double immunostaining: For brain tissue studies, double immunostaining with astrocyte markers (GFAP) can help confirm the cellular source of ORM2 expression, as studies have shown astrocytes are major producers of ORM2 in the inflamed brain .

How can ORM2 antibodies be utilized in neuroinflammation research?

ORM2 antibodies have emerged as valuable tools in neuroinflammation research following the discovery that astrocytes are major cellular sources of ORM2 in the inflamed brain. Researchers can employ these antibodies in several sophisticated approaches:

• Cell-specific expression analysis: Use immunofluorescence co-staining with ORM2 antibodies and cell-specific markers (GFAP for astrocytes, Iba1 for microglia) to determine the cellular sources of ORM2 in various neuroinflammatory conditions.

• Mechanistic studies: Investigate ORM2's role in blocking the interaction between CCL4 and C-C chemokine receptor type 5, which inhibits microglial migration and activation during neuroinflammation .

• Therapeutic potential assessment: Evaluate the effects of recombinant ORM2 protein treatment on microglial production of proinflammatory mediators and microglia-mediated neurotoxicity, as evidence suggests ORM2 decreases these inflammatory processes .

• Biomarker development: Studies have shown significantly higher plasma levels of ORM2 in patients with cognitive impairment compared to normal subjects, suggesting potential for ORM2 antibodies in developing diagnostic assays .

• Intervention studies: Monitor changes in ORM2 expression following experimental treatments for neuroinflammatory conditions, potentially providing mechanistic insights into treatment efficacy.

What is the significance of ORM2 in cancer research and how are antibodies employed in this field?

ORM2 has been identified as a potential tumor suppressor in hepatocellular carcinoma (HCC), with significant implications for cancer research:

• Expression correlation studies: ORM2 antibodies enable researchers to assess the correlation between ORM2 expression and clinical parameters in tumor samples. Studies have demonstrated that ORM2 expression is negatively associated with histological grade of HCC and intrahepatic metastasis, as shown in the following data table :

• Functional studies: Researchers use ORM2 antibodies to validate knockdown or overexpression of ORM2 in cancer cell lines, enabling investigation of its effects on proliferation, migration, and invasion.

• Regulatory mechanism exploration: ORM2 antibodies help elucidate the regulatory mechanisms controlling ORM2 expression, such as the C/EBPβ transcription factor, which has been shown to upregulate ORM2 .

• Prognostic marker development: Based on the correlation with histological grade and metastasis, researchers are investigating ORM2 as a potential prognostic marker in HCC, with antibodies being central to developing such applications.

How can researchers investigate ORM2 interactions with inflammatory pathways?

ORM2 plays significant roles in modulating inflammatory responses, and researchers can employ several approaches to study these interactions:

• Co-immunoprecipitation: Use ORM2 antibodies to pull down protein complexes and identify interaction partners involved in inflammatory signaling pathways.

• Inflammatory cytokine profiling: Measure changes in inflammatory mediator production following ORM2 manipulation (knockdown or overexpression) using antibody-based techniques such as ELISA or cytokine arrays.

• Receptor binding studies: Investigate ORM2's interaction with chemokine receptors, particularly its ability to block the interaction between CCL4 and CCR5, using competitive binding assays with labeled chemokines .

• In vivo inflammation models: Monitor the effects of ORM2 modulation in animal models of inflammation, using antibodies to track expression changes in different tissues and cell types. For example, studies have used lentiviral shRNA-mediated Orm2 knockdown to demonstrate enhanced LPS-induced proinflammatory cytokine gene expression and microglial activation in the hippocampus .

• Clinical correlation studies: Investigate the relationship between ORM2 levels and inflammatory markers in patient samples to establish clinical relevance of research findings.

What are common challenges with ORM2 western blotting and how can they be addressed?

Researchers frequently encounter specific challenges when detecting ORM2 by western blotting:

• Detection of glycosylated forms: ORM2 undergoes extensive N-glycosylation, which can result in diffuse bands or multiple bands of varying molecular weights. Researchers can address this by:

  • Using PNGase F or other deglycosylation enzymes to remove N-linked glycans before SDS-PAGE

  • Running longer gels with greater resolving power for the 20-30 kDa range

  • Including positive control samples (e.g., recombinant ORM2) to verify band identity

• Cross-reactivity with ORM1: Due to high sequence similarity between ORM1 and ORM2, antibody cross-reactivity may occur. Researchers should:

  • Thoroughly validate antibody specificity using knockout/knockdown controls

  • Consider using recombinant monoclonal antibodies with validated specificity

  • Compare multiple antibodies targeting different epitopes

• Low endogenous expression: Outside of liver tissue and inflammatory conditions, ORM2 expression may be low in many tissues. To improve detection:

  • Use more sensitive detection systems (e.g., chemiluminescent substrates with longer exposure times)

  • Concentrate proteins by immunoprecipitation before western blotting

  • Consider enriching for secreted proteins when analyzing culture supernatants

• Membrane optimization: Due to ORM2's relatively small size and high glycosylation:

  • Use PVDF membranes rather than nitrocellulose for better protein retention

  • Optimize transfer conditions (lower voltage for longer time)

  • Consider using transfer buffers specifically designed for glycoproteins

How can researchers optimize immunohistochemical detection of ORM2 in different tissue types?

Different tissue types present unique challenges for ORM2 immunohistochemistry. Here are tissue-specific optimization strategies:

For liver tissue (high endogenous expression):

• Use lower antibody concentrations (1:500-1:1000)

• Shorter primary antibody incubation times may be sufficient

• Careful titration is important to avoid signal saturation

For brain tissue (variable expression):

• Longer primary antibody incubation (overnight at 4°C)

• More rigorous antigen retrieval may be necessary

• Signal amplification systems can help detect lower expression levels

• Consider fluorescence-based detection for co-localization studies with cell-type markers

For tumor tissues (heterogeneous expression):

• Include positive control tissues on the same slide

• Use standardized scoring systems to account for heterogeneity

• Consider automated staining platforms for greater consistency

• Multiple antibodies recognizing different epitopes may provide more robust results

General optimization strategies:

• Perform serial dilutions of primary antibody to determine optimal concentration

• Compare different antigen retrieval methods (heat vs. enzymatic, different pH buffers)

• Optimize blocking conditions to reduce background staining

• Include appropriate positive and negative controls in each experiment

What emerging applications are being developed for ORM2 antibodies?

The field of ORM2 research is evolving rapidly, with several innovative applications emerging:

• Therapeutic antibody development: Based on ORM2's anti-inflammatory properties in neuroinflammation, researchers are exploring antibody-based approaches to modulate ORM2 function or delivery for treating neuroinflammatory diseases .

• Single-cell analysis: Integration of ORM2 antibodies into single-cell protein profiling techniques to understand cell-specific expression patterns in heterogeneous tissues.

• Proximity ligation assays: Advanced techniques combining antibody recognition with DNA amplification to visualize and quantify ORM2 protein interactions with high sensitivity and spatial resolution.

• Biomarker development: Development of highly sensitive immunoassays for measuring ORM2 in various biological fluids as potential biomarkers for inflammatory conditions or cancer progression .

• In vivo imaging: Development of labeled ORM2 antibodies for tracking expression in animal models using various imaging modalities.

The expanding understanding of ORM2's roles in neuroinflammation and cancer suggests that antibody-based applications will continue to grow, particularly as therapeutic strategies targeting ORM2 pathways develop further.

How might systems biology approaches incorporate ORM2 antibody data?

Systems biology approaches offer powerful frameworks for integrating ORM2 antibody-generated data into comprehensive biological understanding:

• Multi-omics integration: Combining ORM2 protein expression data (from antibody-based techniques) with transcriptomics, metabolomics, and other datasets to build comprehensive models of inflammatory or cancer networks.

• Pathway analysis: Using ORM2 protein interaction data to refine pathway models, particularly in inflammatory signaling networks where ORM2 plays modulatory roles.

• Network pharmacology: Identifying potential therapeutic targets based on ORM2's position within protein-protein interaction networks, especially in the context of neuroinflammatory diseases .

• Computational modeling: Developing predictive models of ORM2 function in different cellular contexts based on quantitative antibody-generated expression data.

• Patient stratification algorithms: Incorporating ORM2 expression patterns from tumor samples with other molecular markers to develop improved patient stratification approaches for personalized medicine in cancer treatment .

These integrative approaches will likely enhance the value of ORM2 antibody data beyond traditional applications, contributing to more holistic understanding of complex biological systems and disease mechanisms.